Cargando…

miR-146a-5p Promotes Angiogenesis and Confers Trastuzumab Resistance in HER2+ Breast Cancer

SIMPLE SUMMARY: Resistance to anti-HER2+ therapy remains the main clinical challenge in the management of the HER2+ breast cancer subtype. The objective of our study was to analyze the involvement of microRNAs in the resistance to trastuzumab. We identified miR-146a-5p as the major dysregulated micr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cabello, Paula, Torres-Ruiz, Sandra, Adam-Artigues, Anna, Forés-Martos, Jaume, Martínez, María Teresa, Hernando, Cristina, Zazo, Sandra, Madoz-Gúrpide, Juan, Rovira, Ana, Burgués, Octavio, Rojo, Federico, Albanell, Joan, Lluch, Ana, Bermejo, Begoña, Cejalvo, Juan Miguel, Eroles, Pilar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10093389/ https://www.ncbi.nlm.nih.gov/pubmed/37046799 http://dx.doi.org/10.3390/cancers15072138

Ejemplares similares

The miRNA-449 family mediates doxorubicin resistance in triple-negative breast cancer by regulating cell cycle factors
por: Tormo, Eduardo, et al.
Publicado: (2019)

The Novel Oral mTORC1/2 Inhibitor TAK-228 Reverses Trastuzumab Resistance in HER2-Positive Breast Cancer Models
por: Sanz-Álvarez, Marta, et al.
Publicado: (2021)

High VEGFR3 Expression Reduces Doxorubicin Efficacy in Triple-Negative Breast Cancer
por: Torres-Ruiz, Sandra, et al.
Publicado: (2023)

The role of miR-26a and miR-30b in HER2+ breast cancer trastuzumab resistance and regulation of the CCNE2 gene
por: Tormo, Eduardo, et al.
Publicado: (2017)

MicroRNA-33b Suppresses Epithelial–Mesenchymal Transition Repressing the MYC–EZH2 Pathway in HER2+ Breast Carcinoma
por: Pattanayak, Birlipta, et al.
Publicado: (2020)

miR‐99a‐5p modulates doxorubicin resistance via the COX‐2/ABCG2 axis in triple‐negative breast cancer: from the discovery to in vivo studies
por: Garrido‐Cano, Iris, et al.
Publicado: (2022)

PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects
por: Rincón, Raúl, et al.
Publicado: (2015)

Role of SALL4 in HER2+ Breast Cancer Progression: Regulating PI3K/AKT Pathway
por: Pattanayak, Birlipta, et al.
Publicado: (2022)

CIP2A as a Key Regulator for AKT Phosphorylation Has Partial Impact Determining Clinical Outcome in Breast Cancer
por: Luque, Melani, et al.
Publicado: (2022)

Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer
por: Adam-Artigues, Anna, et al.
Publicado: (2022)

The Hippo Pathway Transducers YAP1/TEAD Induce Acquired Resistance to Trastuzumab in HER2-Positive Breast Cancer
por: González-Alonso, Paula, et al.
Publicado: (2020)

Targeted Therapy Modulates the Secretome of Cancer-Associated Fibroblasts to Induce Resistance in HER2-Positive Breast Cancer
por: Luque, Melani, et al.
Publicado: (2021)

Non-canonical NF-κB pathway activation predicts outcome in borderline oestrogen receptor positive breast carcinoma
por: Rojo, Federico, et al.
Publicado: (2016)

HDAC5 Inhibitors as a Potential Treatment in Breast Cancer Affecting Very Young Women
por: Oltra, Sara S., et al.
Publicado: (2020)

Expression of Phosphorylated BRD4 Is Markedly Associated with the Activation Status of the PP2A Pathway and Shows a Strong Prognostic Value in Triple Negative Breast Cancer Patients
por: Sanz-Álvarez, Marta, et al.
Publicado: (2021)

Identification of a Two-MicroRNA Signature in Plasma as a Novel Biomarker for Very Early Diagnosis of Breast Cancer
por: Adam-Artigues, Anna, et al.
Publicado: (2021)

Oral Selective Estrogen Receptor Degraders (SERDs) as a Novel Breast Cancer Therapy: Present and Future from a Clinical Perspective
por: Hernando, Cristina, et al.
Publicado: (2021)

Thymidylate synthase expression as a predictive biomarker of pemetrexed sensitivity in advanced non-small cell lung cancer
por: Chamizo, Cristina, et al.
Publicado: (2015)

Delivery of miR-200c-3p Using Tumor-Targeted Mesoporous Silica Nanoparticles for Breast Cancer Therapy
por: Garrido-Cano, Iris, et al.
Publicado: (2023)

Clinical Impact of New Treatment Strategies for HER2-Positive Metastatic Breast Cancer Patients with Resistance to Classical Anti-HER Therapies
por: Tapia, Marta, et al.
Publicado: (2023)

Circulating miR-99a-5p Expression in Plasma: A Potential Biomarker for Early Diagnosis of Breast Cancer
por: Garrido-Cano, Iris, et al.
Publicado: (2020)

Circulating miR-30b-5p levels in plasma as a novel potential biomarker for early detection of breast cancer
por: Adam-Artigues, A., et al.
Publicado: (2021)

Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer
por: Madoz-Gúrpide, Juan, et al.
Publicado: (2015)

Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial
por: Alba, E, et al.
Publicado: (2014)

Low MicroRNA-19b Expression Shows a Promising Clinical Impact in Locally Advanced Rectal Cancer
por: Rubio, Jaime, et al.
Publicado: (2021)

Validation of microRNA-199b as A Promising Predictor of Outcome and Response to Neoadjuvant Treatment in Locally Advanced Rectal Cancer Patients
por: Cristóbal, Ion, et al.
Publicado: (2021)

MicroRNA-19b Plays a Key Role in 5-Fluorouracil Resistance and Predicts Tumor Progression in Locally Advanced Rectal Cancer Patients
por: Santos, Andrea, et al.
Publicado: (2022)

Tumor-Infiltrating Lymphocytes and Immune Response in HER2-Positive Breast Cancer
por: Luque, Melani, et al.
Publicado: (2022)

Potential therapeutic value of miR‐425‐5p in metastatic colorectal cancer
por: Cristóbal, Ion, et al.
Publicado: (2016)

Deregulation of SET is Associated with Tumor Progression and Predicts Adverse Outcome in Patients with Early-Stage Colorectal Cancer
por: Cristóbal, Ion, et al.
Publicado: (2019)

MicroRNA-199b Deregulation Shows a Strong SET-Independent Prognostic Value in Early-Stage Colorectal Cancer
por: Cristóbal, Ion, et al.
Publicado: (2020)

A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer patients
por: Pineda, Begoña, et al.
Publicado: (2019)

Pyrosequencing-Based Assays for Rapid Detection of HER2 and HER3 Mutations in Clinical Samples Uncover an E332E Mutation Affecting HER3 in Retroperitoneal Leiomyosarcoma
por: González-Alonso, Paula, et al.
Publicado: (2015)

Comment on ‘MicroRNA-214 suppresses growth, migration and invasion through a novel target, high mobility group AT-hook 1, in human cervical and colorectal cancer cells’
por: Cristóbal, Ion, et al.
Publicado: (2017)

MicroRNA-199b Downregulation Confers Resistance to 5-Fluorouracil Treatment and Predicts Poor Outcome and Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer Patients
por: Cristóbal, Ion, et al.
Publicado: (2020)

Immunological Landscape of HER-2 Positive Breast Cancer
por: Moragon, Santiago, et al.
Publicado: (2022)

Breast Cancer in Very Young Patients in a Spanish Cohort: Age as an Independent Bad Prognostic Indicator
por: Martínez, María Teresa, et al.
Publicado: (2019)

miRNA Expression Analysis: Cell Lines HCC1500 and HCC1937 as Models for Breast Cancer in Young Women and the miR-23a as a Poor Prognostic Biomarker
por: Oltra, Sara S, et al.
Publicado: (2020)

The Antitumor Effect of Metformin Is Mediated by miR-26a in Breast Cancer
por: Cabello, Paula, et al.
Publicado: (2016)

Phosphorylated protein phosphatase 2A determines poor outcome in patients with metastatic colorectal cancer
por: Cristóbal, I, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_jaeg5hseb455habkg44tmajugj